StockData

Canopy Growth vs Cronos

CGC and CRON side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CGC and CRON compare

Cronos grew revenue faster over the last twelve months (55.8% versus 10.7% for Canopy Growth).

Cronos keeps more of each dollar of sales as profit, with a net margin of 28.0% compared with −87.0% at Canopy Growth.

Cronos scores higher on the StockData Score (15 against 3 for Canopy Growth), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCGCCRON
Size and price
Market cap–$1.2B
Share price$0.561$3.38
Change, 1 year−52.8%33.1%
Change, 5 years−99.5%−31.4%
Beta (5Y)1.890.85
Employees1,128610
StockData Score
Total score315 (better)
Valuation score03 (better)
Growth score13 (better)
Performance score13 (better)
Health score16 (better)
Dividend score00
Valuation
P/E–19.9×
P/S–6.0×
P/B–1.2×
EV/EBITDA–36.6×
P/FCF–19.0×
FCF yield–5.3%
Fair value–$3.62
Margin of safety–6.7%
Growth
Revenue growth (TTM)10.7%55.8% (better)
Revenue growth, 5Y average−12.2%25.7% (better)
Net income growth (TTM)–60.2%
EPS growth (TTM)–70.0%
Profitability
Gross margin24.4%46.6% (better)
Operating margin−54.2%3.4% (better)
Net margin−87.0%28.0% (better)
FCF margin−25.8%31.7% (better)
Return on equity–5.4%
Return on invested capital–2.4%
Financial health
Debt / equity–0.00
Interest coverage−3.7×–
Current ratio2.8212.71 (better)
Altman Z-score–11.76
Piotroski F-score57 (better)
Dividends and buybacks
Buyback yield–3.7%
Shareholder yield–3.7%
Ownership
Held by institutions6.9%12.9%
Held by insiders1.0%7.0%
Insider net buying, 12 months−$393K–
Short interest, % of float–1.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.